Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
nivolumab
Bristol-Myers Squibb Pharma EEIG
L01XC17
nivolumab
Antineoplastic and immunomodulating agents, Monoclonal antibodies
Carcinoma, Non-Small-Cell Lung
Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Withdrawn
2015-07-20
28 B. PACKAGE LEAFLET Medicinal product no longer authorised 29 PACKAGE LEAFLET: INFORMATION FOR THE USER NIVOLUMAB BMS 10 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION nivolumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. It is important that you keep the Alert Card with you during treatment. If you have any further questions, ask your doctor. If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Nivolumab BMS is and what it is used for 2. What you need to know before you use Nivolumab BMS 3. How to use Nivolumab BMS 4. Possible side effects 5. How to store Nivolumab BMS 6. Contents of the pack and other information 1. WHAT NIVOLUMAB BMS IS AND WHAT IT IS USED FOR Nivolumab BMS is a medicine used to treat advanced non-small cell lung cancer (a type of lung cancer) in adults. It contains the active substance nivolumab, which is a monoclonal antibody, a type of protein designed to recognise and attach to a specific target substance in the body. Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body’s natural defences). By attaching to PD-1, nivolumab blocks its action and prevents it from switching off your T cells. This helps increase their activity against the lung cancer cells. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NIVOLUMAB BMS _ _ YOU SHOULD NOT BE GIVEN NIVOLUMAB BMS if you are ALLERGIC to nivolumab or any of the other ingredients of this medicine (listed in section 6 "Contents of the pack and other i Przeczytaj cały dokument
1 _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Nivolumab BMS 10 mg/mL concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 10 mg of nivolumab. One vial of 4 mL contains 40 mg of nivolumab. One vial of 10 mL contains 100 mg of nivolumab. Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology. Each mL of concentrate contains 0.1 mmol (or 2.5 mg) sodium. Excipient with known effect For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to opalescent, colourless to pale yellow liquid that may contain few light particles. The solution has a pH of approximately 6.0 and an osmolality of approximately 340 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment must be initiated and supervised by physicians experienced in the treatment of cancer. The recommended dose of Nivolumab BMS is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient. Posology Dose escalation or reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability. Guidelines for permanent discontinuation or withholding of doses are described in Table 1. Detailed guidelines for the management of immune-related adverse reactions are described in section 4 Przeczytaj cały dokument